Quality and Regulatory Sourcebook March 2022
Read the article:
Supply Chain Considerations for Ensuring Quality
Read the eBook:
BioPharm International's Quality and Regulatory Sourcebook eBook
Disruptions in the bio/pharmaceutical supply chain can have serious impacts on the quality and availability of life-saving medicines.
WRIGHTSTUDIO - STOCK.ADOBE.COM
Disruptions in the bio/pharmaceutical supply chain that impact capacity and capabilities result in longer lead times for drug products, according to Ari Ojinaka, production manager at Astrea Bioseparations. The past two years of the COVID-19 pandemic have highlighted the importance of a healthy supply chain. “Through the pandemic, we have witnessed a significant reduction in inter-country transportation of goods and services and in-country COVID-19 restriction impacting capacity and capabilities to manufacture,” says Ojinaka.
Pharmaceutical Technology spoke with Ojinaka as well as Steve Kirk, vice-president Global Procurement, Catalent; Vincent Colicchio, vice-president, Supply Chain and External Manufacturing, Dr. Reddy’s Laboratories; and Hamilton Lenox, senior vice president–Business Development & Operations at LGM Pharma about the impact of COVID-19 on the supply chain and what companies can do to ensure the quality of their products.
Read this article in BioPharm International's March 2022 Quality and Regulatory Sourcebook eBook.
Read the article:
Supply Chain Considerations for Ensuring Quality
Read the eBook:
BioPharm International's Quality and Regulatory Sourcebook eBook
About the author
Susan Haigney is managing editor of BioPharm International.
Article Details
BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 33-36
Citation
When referring to this article, please cite it as S. Haigney, “Supply Chain Considerations for Ensuring Quality," BioPharm International's Quality and Regulatory Sourcebook eBook (March 2022).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.